微波消融与射频消融治疗米兰标准内肝细胞癌:倾向性评分分析
该研究比较微波消融(MWA)与射频消融(RFA)治疗米兰标准内原发性肝细胞癌的疗效,纳入2002年1月至2017年1月MWA组126例、RFA组436例并进行倾向性评分匹配。匹配后MWA的5年总生存率和无复发生存率优于RFA,但对≤3 cm单发肝癌两者疗效相当。
要点
- 匹配后MWA较RFA改善肝细胞癌的5年总生存率(79.3% vs 68.4%,P=0.021)。
- 匹配后MWA较RFA改善5年无复发生存率(27.9% vs 6.4%,P<0.001)。
- ≤3 cm单发肝癌中MWA与RFA的5年总生存率和无复发生存率无显著差异。
核心结论
- 在米兰标准内肝细胞癌中,RFA疗效劣于MWA,但对≤3 cm单发肝癌RFA与MWA疗效相当。
研究设计与样本
- 倾向性评分匹配分析,纳入2002年1月至2017年1月MWA组126例与RFA组436例原发性肝细胞癌患者,比较肿瘤学结局。
主要发现
- 匹配前总体患者中,MWA与RFA的5年总生存率相似(80.1% vs 75.8%,P=0.190),MWA的5年无复发生存率优于RFA(28.1% vs 19.6%,P=0.036)。
- 匹配前≤3 cm单发肝癌中,MWA与RFA的5年总生存率相当(81.8% vs 77.1%,P=0.170),MWA的5年无复发生存率优于RFA(34.6% vs 24.0%,P=0.042)。
- 匹配后肝细胞癌中,MWA的5年总生存率(79.3% vs 68.4%,P=0.021)和5年无复发生存率(27.9% vs 6.4%,P<0.001)均优于RFA。
- 匹配后≤3 cm单发肝癌中,MWA与RFA的5年总生存率(81.2% vs 66.3%,P=0.062)和无复发生存率(37.7% vs 17.4%,P=0.088)均无显著差异。
- Cox分析显示,RFA方式、肿瘤位于风险区域和低血清白蛋白水平是总生存的不良预后因素;RFA方式、多发肿瘤、肿瘤大小和低血清白蛋白水平是无复发生存的不良预后因素(均P<0.05)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether microwave ablation (MWA) challenges the standard role of radiofrequency ablation (RFA) in treating early-stage hepatocellular carcinoma (HCC) remains unclear. AIM: To compare the efficacy of MWA vs RFA for treating primary HCC within the Milan criteria. METHODS: From January 2002 to January 2017, the oncological outcomes after MWA (126 patients) and RFA (436 patients) were analysed by propensity score matching. RESULTS: Before propensity score matching, for overall patients, MWA resulted in similar 5-year overall survival to RFA (80.1% vs 75.8%, P = 0.190) but better 5-year recurrence-free survival (28.1% vs 19.6%, P = 0.036). For solitary HCC ≤ 3 cm, MWA resulted in comparable 5-year overall survival (81.8% vs 77.1%, P = 0.170) to RFA but better 5-year recurrence-free survival (34.6% vs 24.0%, P = 0.042). After propensity score matching, MWA resulted in better 5-year overall survival (79.3% vs 68.4%, P = 0.021) and 5-year recurrence-free survival (27.9% vs 6.4%, P < 0.001) than RFA for HCC. For solitary HCC ≤3 cm, MWA resulted in comparable 5-year overall survival (81.2% vs 66.3%, P = 0.062) and 5-year recurrence-free survival (37.7% vs 17.4%, P = 0.088) to RFA. In Cox analysis, RFA modality, tumours located in risk areas and low serum albumin levels were unfavourable prognostic factors for overall survival. RFA modality, multiple tumours, tumour size and low serum albumin levels were unfavourable prognostic factors for recurrence-free survival (all P < 0.05). CONCLUSIONS: RFA is inferior to MWA for treating HCC within the Milan criteria, but has comparable efficacy to MWA for solitary HCC ≤ 3 cm.
引用
- Liu W, Zheng Y, He W, et al. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Aliment Pharmacol Ther. 2018. PMID: 30063081. doi:10.1111/apt.14929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。